Literature DB >> 7327092

[Myasthenia syndrome during chloroquine treatment (author's transl)].

F Schumm, H Wiethölter, A Fateh-Moghadam.   

Abstract

Myasthenic reaction with partial neuromuscular block in the electromyogram and increased antibodies against acetylcholine-receptor protein developed during chloroquine administration over two months in a 52-year-old man known for eight years ot have rheumatoid arthritis. When the drug was discontinued and pyridostigmine administration begun, myasthenia improved within six weeks and had completely disappeared after three months. During the same period abnormal neuromuscular transmission regressed. Also, the significantly increased antibodies against acetylcholine-receptor protein became normal. It remains undecided whether this was a drug-induced myasthenia gravis or only a latent myasthenia manifested by the drug.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7327092     DOI: 10.1055/s-2008-1070589

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

Review 1.  The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.

Authors:  M Jallouli; D Saadoun; B Eymard; G Leroux; J Haroche; D Le Thi Huong; C De Gennes; C Chapelon; O Benveniste; B Wechsler; P Cacoub; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  J Neurol       Date:  2011-12-08       Impact factor: 4.849

2.  Hydroxychloroquine and Myasthenia Gravis-Can One Take This Risk?

Authors:  Arunmozhimaran Elavarasi; Vinay Goyal
Journal:  Ann Indian Acad Neurol       Date:  2020-06-10       Impact factor: 1.383

3.  Myasthenia gravis: overlap with 'polyendocrine' autoimmunity.

Authors:  W A Scherbaum; F Schumm; B Maisch; C Müller; A Fateh-Moghadam; S H Flüchter; F J Seif; G F Bottazzo; P A Berg
Journal:  Klin Wochenschr       Date:  1983-05-16

4.  Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes.

Authors:  Elie Naddaf; Pritikanta Paul; Omar F AbouEzzeddine
Journal:  Front Neurol       Date:  2021-02-02       Impact factor: 4.003

5.  MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine.

Authors:  Shalini Bhaskar; Mohammed Fauzi Bin Abdul Rani
Journal:  Case Rep Med       Date:  2022-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.